What are we trying to accomplish?
At the conclusion of this trial, we expect to have sufficient evidence as to whether reducing the propensity for thrombus formation and/or increasing fibrinolytic activity can prevent the progression of atherosclerosis and cognitive decline.
These results will provide novel and important data that will be informative concerning primary prevention through the atherothrombotic pathway. Providing evidence for a reduction in atherosclerosis progression and cognitive decline with nattokinase is likely to shift the current clinical paradigm for the prevention of these chronic age-related processes. In addition, such evidence will serve to create a new field of discovery and opportunity for prevention of cardiovascular disease and dementia.
NAPS is under the direction of Dr. Howard Hodis, M.D. at the Atherosclerosis Research Unit (ARU) at the University of Southern California.
Currently NAPS is closed for recruiting volunteers.